Kymera Therapeutics (KYMR) Revenue (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Revenue for 8 consecutive years, with $34.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue rose 55.5% year-over-year to $34.4 million; the TTM figure through Mar 2026 stood at $51.5 million (down 12.58% YoY), while the FY2025 annual figure was $39.2 million, down 16.7% from the prior year.
• Revenue improved to $34.4 million in Q1 2026 per KYMR's latest filing, from $2.9 million in the prior quarter.
• Across five years, Revenue topped out at $47.9 million in Q4 2023 and bottomed at $2.8 million in Q3 2025.
• Historically, Revenue has averaged $14.5 million across 5 years, with a median of $10.3 million in 2024.
• Annual changes were most pronounced in 2023 — Revenue soared 196.7% — and 2024, when it sank 84.56%.
• Kymera Therapeutics' Revenue stood at $16.1 million in 2022, then soared by 196.7% to $47.9 million in 2023, then tumbled by 84.56% to $7.4 million in 2024, then slumped by 61.18% to $2.9 million in 2025, then soared by 1097.39% to $34.4 million in 2026.
• Business Quant data shows KYMR's Revenue at $34.4 million in Q1 2026, $2.9 million in Q4 2025, and $2.8 million in Q3 2025.